The upcoming earnings report for Ginkgo Bioworks Holdings, Inc. (DNA) is set for Monday, May 4th, with a consensus EPS estimate of -1.21115.
Today, DNA is priced at $7.62, showing a decrease of -2.49% from the previous close. Trading volume stands at $112,398, 9.36% higher than the average.
In the latest quarterly earnings report on Wednesday, February 25th, DNA reported an EPS of -1.45608, beating the consensus estimate of -1.8.
The company experienced a net cash inflow of $54.36 million, with operating cash flow at -$47.68 million and free cash flow at -$63 million.
DNA generated $33.40 million in revenue, resulting in a net loss of $80.75 million. The EPS and diluted EPS were both reported at -$1.43.
Key ratios show a quick ratio of 4.92, gross profit margin of 124.4%, and a negative net profit margin of -241.8%. The price-to-book ratio is 0.91.
Total assets amount to $1.12 billion, with total liabilities at $611.11 million. Cash and cash equivalents stand at $167.20 million.
This real-time financial report provides a comprehensive overview of DNA's current status and financial performance.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.